SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules...
Hence then, the article about ark biopharmaceutical receives china marketing authorization for azstarys for the treatment of adhd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD )
Also on site :
- Thriller! Rylan Sevilla’s fourth-quarter heroics lift No. 17 Dougherty Valley past No. 9 Bishop O’Dowd
- Nordstrom Rack Has a 'Gorgeous' 5-Piece Tennis Bracelet Set on Sale for Just $20: 'The Sparkle Is Unreal'
- CES 2026: Guangfan Technology Reveals Lightwear, Introducing World's First Vision-Enabled AI Earphones